Growth suppression of Mouse Pituitary Corticotroph Tumor AtT20 cells by Curcumin: A model for treating Cushing's disease

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Bangaru, Madhavi Latha Yadav ^a   Woodliff, Jeffrey ^a   Raff, Hershel ^a   Kansra, Sanjay ^a,b  

^a ST LUKE S MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; PROTEIN BCL XL; ANTINEOPLASTIC AGENT; CORTICOTROPIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ACTH SECRETING ADENOMA; ANIMAL CELL; APOPTOSIS; ARTICLE; ATT20 CELL; CELL PROLIFERATION; CELL SECRETION; CUSHING DISEASE; DOWN REGULATION; GROWTH INHIBITION; MEMBRANE DEPOLARIZATION; MOUSE; NONHUMAN; PLASMA CELL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR CELL LINE; ANIMAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; PATHOLOGY; SECRETION;

ACTH-SECRETING PITUITARY ADENOMA; ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; NF-KAPPA B; PITUITARY ACTH HYPERSECRETION;

EID: 77956297954     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009893     Document Type: Article

References (34)

1. Miller M, Chen S, Woodliff J, Kansra S (2008) Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells. Endocrinology 149: 4158-4167.
2. Katznelson L, Kleinberg D, Vance ML, Stavrou S, Pulaski KJ, et al. (2001) Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol (Oxf) 54: 183-188.
3. Ross EJ, Linch DC (1982) Cushing's syndrome-killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 2: 646-649.
4. Miyoshi T, Otsuka F, Takeda M, Inagaki K, Suzuki J, et al. (2004) Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin- secreting macroadenoma. J Endocrinol Invest 27: 1055-1059.
5. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, et al. (2009) Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94: 115-122.
6. Heaney AP, Fernando M, Yong WH, Melmed S (2002) Functional PPARgamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8: 1281-1287.
7. Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, et al. (2001) Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 108: 1123-1131.
8. Ozer E, Canda MS, Ulukus C, Guray M, Erbayraktar S (2003) Expression of Bcl-2, Bax and p53 proteins in pituitary adenomas: an immunohistochemical study. Tumori 89: 54-59.
9. Lud CJ, Harrington B, Ordonez S (2000) Bcl-2 overexpression attenuates dopamine-induced apoptosis in an immortalized neural cell line by suppressing the production of reactive oxygen species. Synapse 35: 228-233.
10. Shah BH, Nawaz Z, Pertani SA, Roomi A, Mahmood H, et al. (1999) Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. Biochem Pharmacol 58: 1167-1172.
11. Singh S, Aggarwal BB (1995) Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 270: 24995-25000.
12. Corson TW, Crews CM (2007) Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 130: 769-774.
13. Ohori H, Yamakoshi H, Tomizawa M, Shibuya M, Kakudo Y, et al. (2006) Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther 5: 2563-2571.
14. Syng-Ai C, Kumari AL, Khar A (2004) Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2. Mol Cancer Ther 3: 1101-1108.
15. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, et al. (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res 21: 2895-2900.
16. Schaaf C, Shan B, Buchfelder M, Losa M, Kreutzer J, et al. (2009) Curcumin acts anti-tumourigenic and hormone-suppressive in murine and human pituitary tumour cells in vitro and in vivo. Endocr Relat Cancer 16(4): 1339-50.
17. Deeb D, Jiang H, Gao X, Al-Holou S, Danyluk AL, et al. (2007) Curcumin [1,7- bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosisinducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway. J Pharmacol exp Ther 321: 616-625.
18. Jee SH, Shen SC, Tseng CR, Chiu HC, Kuo ML (1998) Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. J Invest Dermatol 111: 656-661.
19. Kamat AM, Sethi G, Aggarwal BB (2007) Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther 6: 1022-1030.
20. Collett GP, Campbell FC (2004) Curcumin induces c-jun N-terminal kinasedependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 25: 2183-2189.
21. Jiang MC, Yang-Yen HF, Lin JK, Yen JJ (1996) Differential regulation of p53, c- Myc, Bcl-2 and Bax protein expression during apoptosis induced by widely divergent stimuli in human hepatoblastoma cells. Oncogene 13: 609-616.
22. Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB (2002) Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 23: 143-150.
23. Shishodia S, Sethi G, Aggarwal BB (2005) Curcumin: getting back to the roots. Ann N Y Acad Sci 1056: 206-217.
24. Shishodia S, Amin HM, Lai R, Aggarwal BB (2005) Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70: 700-713.
25. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, et al. (1997) Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100: 2952-2960.
26. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, et al. (1999) The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119-127.
27. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, et al. (2002) Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 52: 183-200.
28. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, et al. (1997) Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100: 2961-2969.
29. Ezzat S, Zhu X, Loeper S, Fischer S, Asa SL (2006) Tumor-derived Ikaros 6 acetylates the Bcl-XL promoter to up-regulate a survival signal in pituitary cells. Mol Endocrinol 20: 2976-2986.
30. Zaldivar V, Magri ML, Zarate S, Jaita G, Eijo G Estradiol increases the Bax/Bcl- 2 ratio and induces apoptosis in the anterior pituitary gland. Neuroendocrinology 90: 292-300.
31. Grad JM, Zeng XR, Boise LH (2000) Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Curr Opin Oncol 12: 543-549.
32. Kirito K, Watanabe T, Sawada K, Endo H, Ozawa K, et al. (2002) Thrombopoietin regulates Bcl-xL gene expression through Stat5 and phosphatidylinositol 3-kinase activation pathways. J Biol Chem 277: 8329-8337.
33. Kansra S, Yamagata S, Sneade L, Foster L, Ben Jonathan N (2005) Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol 239: 27-36.
34. Klein SB, Fisher GJ, Jensen TC, Mendelsohn J, Voorhees JJ, et al. (1992) Regulation of TGF-alpha expression in human keratinocytes: PKC-dependent and -independent pathways. J Cell Physiol 151: 326-336.